Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03357510
Other study ID # Fe_AcuteGOS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 16, 2018
Est. completion date June 24, 2018

Study information

Verified date June 2018
Source Swiss Federal Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether single doses of the prebiotic galacto-oligosaccharide (GOS) added to iron-fortified meals with micronutrient powders increase iron absorption compared to a 3 weeks pre-feeding of GOS.


Description:

Infants and young children in sub-Saharan Africa have high rates of iron deficiency anemia (IDA), which adversely affects their growth and cognitive development. In-home iron fortification of complementary foods using micronutrient powders (MNPs) reduces risk for IDA by ensuring that the iron needs of infants and young children are met with-out changing their traditional diet. However, MNPs containing a high dose of 12.5 mg of iron adversely affect the African infant gut microbiome by decreasing beneficial 'barrier' commensals, like Bifidobacteria, while increasing enterobacteria, specific enteropathogens, e.g. pathogenic Escherichia coli. Furthermore, the risk for gut inflammation, diarrhoea and respiratory tract infections (RTIs) might increase. Thus, there is an urgent need to find safer formulations of iron fortification for African infants. In a recent trial in Kenya, the investigators demonstrated that iron dose in MNP can be reduced to 5 mg and still be efficacious in reducing anemia and all measures of iron deficiency. Also, addition of prebiotic to it reduces adverse effects on the gut of the infant, resulting in greater abundances of Bifidobacteria and Lactobacilli, lower abundances of virulence and toxin genes of pathogens and less enterocyte damage and a lower incidence of treated RTIs. Further, the investigators also showed that prior consumption of the galacto-oligosaccharide (GOS) for 3 weeks increases iron absorption from the MNP containing sodium iron ethylenediaminetetraacetate (NaFeEDTA) and ferrous fumarate (FeFum), possibly reflecting greater colonic iron absorption.

To complement the results of the enhancing effect on iron absorption of GOS and to confirm the suggested mechanism of being colonic iron absorption, the investigators would like to test whether GOS increases iron absorption if it is given without 3 weeks of pre-feeding via a potential change of the meal matrix rather than changes in the gut microbiome as seen with the 3 weeks of prior consumption of GOS.

The above mentioned studies showing an increase in RTIs with consumption of the high iron dose MNP and recently conducted study that showed a decrease in RTIs if the prebiotic GOS is added to the MNP need further investigation to understand the underlying mechanism on how iron and prebiotic influence the occurrence of RTIs. To take a first step, the investigators would therefore like to investigate the nasopharyngeal microbiome of infants consuming iron syrup, as changes in pathogen colonization of the respiratory epithelium is one possible mechanism on how iron and prebiotics might influence the incidence of RTIs.

The investigators will compare the fractional iron absorption (FIA) of the iron with and without co-consumption of the GOS prebiotic in Kenyan infants consuming a maize porridge. This study will follow on recently concluded studies in the Kwale County. 22 infants will be enrolled. On 2 consecutive study days, these infants will consume a test meal with 2 iron compounds (NaFeEDTA and FeFum) and a reference test meal with ferrous sulfate (FeSO4) all with GOS. Fourteen days later, they will consume all the test meals without GOS on 2 consecutive study days. The investigators will then assess the relative effects of co-consumption of GOS on absorption of the three compounds. The hypothesis is that co-consumption of GOS with the iron in the test meals will not increase absorption of iron from the three compounds, compared to no co-consumption of GOS.

In the same infants collect a fecal sample and a nasopharyngeal sample will be collected to determine the microbiome changes before and after consumption of iron containing syrups.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date June 24, 2018
Est. primary completion date June 3, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 14 Months
Eligibility Inclusion Criteria:

- Age of 6-14 months at baseline

- Assessment of good health as assessed by professional staff at Msambweni District Hospital

- The caregiver is willing to participate in the study

- The informed consent form has been read and signed by the caregiver (or has been read out to the caregiver in case of illiteracy)

Exclusion Criteria:

- Hemoglobin <70 g/L

- Severe underweight (Z-score weight-for-age <-3)

- Severe wasting (Z-score weight-for-height<-3)

- Chronic or acute illness or other conditions that in the opinion of the Principle Investigator (PI) or co-researchers would jeopardize the safety or rights of a par-ticipant in the trial or would render the participant unable to comply with the protocol

- Participants taking part in other studies requiring the drawing of blood

- Not planning long-term residence in study site

- Regular intake (>2 days) of iron-containing mineral and vitamin supplements or fortified foods within the last 2 months

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
FeSO4 with GOS
7.5 g of the prebiotic galacto-oligosaccharides (GOS) and 5 mg ferrous sulfate (FeSO4) to test meals; Prebiotic fibers, are know to positively affect the gut microbiota composition by increasing populations of healthy bacteria such as bifidocbacteria and lactobacilli and creating a strong barrier against pathogens in the human intestine; GOS are a mixture of various galactose-based di- and oligosaccharides of 2-8 saccharide units of different structure that are enzymatically produced from lactose.
FeSO4 with no GOS
no prebiotic galacto-oligosaccharide (GOS) to test meals but 5 mg ferrous sulfate (FeSO4)
FeFum+NaFeEDTA with GOS
7.5 g of the prebiotic galacto-oligosaccharides (GOS) to test meals and 5 mg of iron mix (2.5 mg ferrous fumarate (FeFum) + 2.5 mg NaFeEDTA); Prebiotic fibers, are know to positively affect the gut microbiota composition by increasing populations of healthy bacteria such as bifidocbacteria and lactobacilli and creating a strong barrier against pathogens in the human intestine; GOS are a mixture of various galactose-based di- and oligosaccharides of 2-8 saccharide units of different structure that are enzymatically produced from lactose.
FeFum+NaFeEDTA with no GOS
7.5 g of the prebiotic galacto-oligosaccharides (GOS) to test meals but 5 mg of iron mix (2.5 mg ferrous fumarate (FeFum) + 2.5 mg NaFeEDTA)

Locations

Country Name City State
Kenya Msambweni District Hopsital Msambweni Kwale County

Sponsors (1)

Lead Sponsor Collaborator
Swiss Federal Institute of Technology

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fractional iron absorption Fractional iron absorption from MNPs containing 3 different iron compounds (FeSO4, NaFeEDTA and FeFum), consumed with and without the prebiotic GOS Measured at 14 days after last test meals (Day 34) from blood draw
Secondary Nasopharyngeal microbiome Infant's nasopharyngeal microbiome before and after one month of iron syrup treatment After Iron absorption study at Day 35 (serves as baseline) and 1 month later at Day 63 (serves as endpoint)
Secondary Gut microbiome Infant's gut microbiome before and after one month of iron syrup treatment After Iron absorption study at Day 35 (serves as baseline) and 1 month later at Day 63 (serves as endpoint)
See also
  Status Clinical Trial Phase
Completed NCT04949165 - Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study N/A
Terminated NCT03218384 - Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency Phase 2
Active, not recruiting NCT03516734 - Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh N/A
Completed NCT03572010 - Stable Iron Isotope Method in HIV+ and HIV- Children N/A
Active, not recruiting NCT03703726 - Iron Absorption From Fortified Extruded Rice Using Different Extruding Temperatures. N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Not yet recruiting NCT05395468 - Diagnosis of Iron Deficiency by Artificial Intelligence Analysis of Eye Photography.
Withdrawn NCT03800446 - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood N/A
Not yet recruiting NCT03353662 - Sub Regional Micronutrient Survey in Ethiopia
Completed NCT03819530 - Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study N/A
Recruiting NCT04144790 - Impact of Iron Supplementation Treatment on Brain Iron Concentrations
Completed NCT03957057 - Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia Phase 3
Completed NCT03642223 - Central and Peripheral Adiposity and Iron Absorption N/A
Not yet recruiting NCT05407987 - Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) Phase 3
Withdrawn NCT03873584 - Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
Enrolling by invitation NCT03897673 - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas N/A
Completed NCT04359368 - Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
Active, not recruiting NCT04778072 - A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects N/A
Enrolling by invitation NCT05750940 - Oxidative Skeletal Muscle Metabolism in Chronic Heart Failure Patients With and Without Iron Deficiency
Recruiting NCT05126901 - Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years Phase 3